AI and Cancer Research ── Pancreatic ── 2026-10-18

Figure for a new paper, MetaPaCS, on pancreatic cancer subtyping. Target: the many subtypes of a heterogenous cancer. Method: predictions from several base classifiers are combined with the initial feature vectors and passed to a meta-learning classifier. Result: leave-one-out cross-validation beat optimized individual base classifiers. It is preclinical computational work, with only the abstract checked. — Image abstract — the whole article on one page (click to enlarge)

1 Pancreatic papers. Lead: MetaPaCS: A Novel Meta‐Learning Framework for Pancreatic Cancer Subtype Identification

Journals covered and how papers are chosen: see the index

Pancreatic cancer: treatment, trials and AI

MetaPaCS: A Novel Meta‐Learning Framework for Pancreatic Cancer Subtype Identification
Advanced Intelligent Systems · 2026-10-15 · Evidence: Preclinical (computational method development with cross-validation on transcriptomic data)
Abstract
Pancreatic cancer (PaC), the third leading cause of cancer related deaths in the United States, is a highly heterogenous malignancy with a multitude of potential subtypes. Each PaC subtype has unique molecular pathways and therapeutic characteristics, which can be used in downstream patient risk stratification and tailored treatment design. Conventional wet‐lab approaches for PaC subtyping (microdissection, histopathological studies, etc.) are laborious, costly, and time‐consuming. To address these concerns, we present MetaPaCS, a novel meta‐learning framework to accurately identify PaC subtypes based on transcriptomics data. Specifically, after preprocessing, the transcriptome‐based feature vectors are classified by multiple base machine learning classifiers, whose diverse prediction outputs are combined with the initial preprocessed feature vectors to constitute a new set of ensemble feature vectors for a meta‐learning classifier. Leave‐one‐out cross‐validation demonstrates that MetaPaCS performs remarkably better optimized individual base classifiers. We believe that MetaPaCS is a promising tool for downstream risk stratification and personalized treatment design.
Journal IF-equivalent: 5.6 (OpenAlex 2-year mean citedness, value as of 2026-10-09, retrieved 2026-10-10; not the official Clarivate IF)
Reference: Peterson NB, Sun M, Wu X, Wang J, Wan S. MetaPaCS: A Novel Meta‐Learning Framework for Pancreatic Cancer Subtype Identification. Advanced Intelligent Systems. 2026 Oct 15 [Epub ahead of print]. doi:10.1002/aisy.70576.
Checked: Abstract only

← Back to this issue